Free Daily Podcast Summary
CME in Minutes: Education in Oncology & Hematology: Daily Summaries Delivered
by Answers in CME
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago13 min
Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation
Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.
- 3 days ago19 min
Sustaining Long-Term Care With ALK TKIs in Metastatic NSCLC: Best Practices for Adverse Event Management
Please visit answersincme.com/KNY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Barbara Melosky, MD, FRCPC; and Alyson Chin, RN, BScN, MN-ACNP(A). In this activity, experts in lung cancer discuss the management of adverse events associated with tyrosine kinase inhibitor use in patients with ALK-positive metastatic non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Identify ALK tyrosine kinase inhibitor (TKI)–related adverse events (AEs) among patients with ALK-positive (ALK+) metastatic non–small-cell lung cancer (mNSCLC); Apply strategies to effectively monitor and manage ALK TKI–related AEs to enhance treatment adherence in patients with ALK+ mNSCLC; and Outline multidisciplinary, patient-centered strategies to optimize care for patients receiving ALK TKIs for ALK+ mNSCLC.
- 1 weeks ago19 min
Case-Based Guidance on Tailoring Treatment Selection for Menopause-Related VMS
Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.
- 2 weeks ago25 min
Going Beyond the Guidelines: Incorporating Patient and Disease Factors to Optimize First-Line Treatment Strategies in LA/mUC
Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.
- 3 weeks ago21 min
Evolving Insights Into EZH 1/2 Inhibition in B- and T-Cell Lymphoma: Expert Perspectives on Latest Advancements
Please visit answersincme.com/NDX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tycel J. Phillips, MD and Steven Horwitz, MD. In this activity, experts in B-cell and T-cell lymphomas discuss EZH inhibitors for non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Discuss the rationale for EZH inhibitors in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL); Describe the clinical profiles of available and emerging EZH inhibitors; and Outline current and potential methods of optimizing EZH inhibitors in clinical practice based on available evidence.
- 3 weeks ago20 min
Answering Clinician Questions About Anemia in Lower-Risk Myelodysplastic Syndromes: Community-Based Strategies to Enhance Long-Term Efficacy
Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.
- Aug 17, 202614 min
Redefining What’s Possible in mTNBC: The Expanding Frontier of TROP2-Directed ADCs
Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.
- Aug 13, 202622 min
Conversations in Gene Expression–Based Testing: A Clinician’s Roadmap to Multidisciplinary Melanoma Care
Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.
About CME in Minutes: Education in Oncology & Hematology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from CME in Minutes: Education in Oncology & Hematology in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's CME in Minutes: Education in Oncology & Hematology daily summary?
It's a free AI-powered email that summarizes new episodes of CME in Minutes: Education in Oncology & Hematology as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the CME in Minutes: Education in Oncology & Hematology podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official CME in Minutes: Education in Oncology & Hematology product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Answers in CME.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does CME in Minutes: Education in Oncology & Hematology release new episodes?
CME in Minutes: Education in Oncology & Hematology publishes every few days. Our AI generates a summary within hours of each new episode.
What topics does CME in Minutes: Education in Oncology & Hematology cover?
CME in Minutes: Education in Oncology & Hematology covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting CME in Minutes: Education in Oncology & Hematology summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.